All In Biotech

Drug Trial Radar · NCT07695597

A Study of SYH2070 Injection in Participants With Mixed Hyperlipidemia

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Mixed Hyperlipidemia

Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Jul 15, 2026

Primary completion

Apr 30, 2027

Study completion Sep 10, 2027

Sponsor

Sponsor type
Industry
First posted
Jul 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-parallel, multicenter phase II clinical trial to evaluate the efficacy and safety of SYH2070 injection in participants with mixed hyperlipidemia.

Conditions

  • Mixed Hyperlipidemia

Interventions

  • SYH2070Drug

    SYH2070 injection, 150 mg, 300 mg, 400 mg, SC, administration duration: 24 weeks

  • PlaceboDrug

    Placebo, SC, administration duration: 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage change in serum TG levels from baseline at week 24Time frame: Baseline through Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.